Background: Depressive disorders are among four leading causes of burden among the
most disabling medical illnesses and antidepressant drugs (AD) occupying leading positions in the
worldwide pharmaceutical market. However, typical AD show prolonged delay, refractory and
adverse side effects.
Methodology: The review analyzes experimental data and theoretical models of possible
antidepressant effect of benzopentathiepine, 8-(trifluoromethyl)-1,2,3,4,5 - benzopentathiepin-6-
amine hydrochloride (TC-2153). The antidepressant effect of TC-2153 is based on its ability to inhibit
striatal enriched protein tyrosine phosphatase (STEP)- an enzyme that plays a key role in the
intraneuronal transduction of signals from receptors of classic neurotransmitters and the brain derived
neurotrophic factor (BDNF). The mechanism underlying antidepressant effect of TC-2153 includes
increase in production as well as intracellular effect of BDNF on neuronal survival and neurogenesis.
Results and Conclusion: There is no visible mechanisms of delay, refractory and adverse side effects
of TC-2153. Thus, TC-2153 is a promising drug of new generation of atypical AD.